Previous Close | 1.6200 |
Open | 1.2600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 79.00 |
Expire Date | 2024-07-12 |
Day's Range | 1.2600 - 1.6200 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
"The EMA's (European Medicines Agency) Committee for Medicinal Products for Human Use(CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation," the Anglo-Swedish drugmaker said. An accelerated assessment aims to speed up the EMA's review of a market authorisation application. AstraZeneca acquired sipavibart from RQ Bio in May 2022.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.